Drugs / Human Papillomavirus (HPV) 16 Monovalent
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00092521 | Dec 2001 → Jul 2007 | cervical cancer, human papilloma virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Papillomavirus (HPV) 16 Monovalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00092521 ↗ |
| Modality | Vaccine | “HPV 16 Monovalent vaccine” NCT00092521 ↗ |
| Route | Intramuscular | “HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.” NCT00092521 ↗ |